Publications by authors named "Pudilova K"
Scand J Gastroenterol
July 2022
Article Synopsis
- The study compares the long-term effectiveness of originator-adalimumab and its biosimilar, SB5-adalimumab, in treating Crohn's disease patients who switched medications versus those who remained on the originator over a period of 104 weeks.
- At 52 weeks, clinical disease activity scores showed no significant difference between the two groups, with similar outcomes on related biological measures.
- However, treatment persistence was notably lower for the SB5-adalimumab group, with local skin reactions being a common reason for discontinuation.
